Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

GSK Ups Its Stake In Theravance

by Ann M. Thayer
April 9, 2012 | A version of this story appeared in Volume 90, Issue 15

GlaxoSmithKline has paid $213 million to increase its stake in South San Francisco-based Theravance by 8.5% to a total of 26.8%. GSK has been a partner of the small-molecule drug discovery firm since 2002. They have collaborated on the development of Relovair, which combines a long-acting β2 agonist with an inhaled corticosteroid to treat respiratory diseases. GSK will soon file for approval of the drug in the U.S. and Europe. The companies are working on another respiratory disease drug that is in Phase II development.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.